6JH Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IN8bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$1.74 |
| 52 Week Low | US$0.23 |
| Beta | -0.051 |
| 11 Month Change | -45.21% |
| 3 Month Change | -67.35% |
| 1 Year Change | -73.63% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6JH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.7% | 2.2% | -1.9% |
| 1Y | -73.6% | -9.8% | 12.3% |
Return vs Industry: 6JH underperformed the German Biotechs industry which returned -9.9% over the past year.
Return vs Market: 6JH underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| 6JH volatility | |
|---|---|
| 6JH Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6JH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6JH's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 39 | William Ho | in8bio.com |
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
IN8bio, Inc. Fundamentals Summary
| 6JH fundamental statistics | |
|---|---|
| Market cap | €11.25m |
| Earnings (TTM) | -€29.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 6JH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6JH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$31.96m |
| Earnings | -US$31.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6JH perform over the long term?
See historical performance and comparison